Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has announced a new pre-clinical antibody program called HuMax-CD32b. This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors.
Subscribe to our email newsletter
The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent triggering of the immune system killing mechanism antibody-dependent cellular cytotoxicity (ADCC). The antibody was shown to be highly effective in suppressing tumor growth in in vivo mouse tumor models in which tumor growth was monitored by highly sensitive bioluminescence imaging.
In animal models, HuMax-CD32b has been shown to induce impressive anti-tumor responses and may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt’s lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.
Jan van de Winkel, chief scientific officer at Genmab, said: “We believe HuMax-CD32b has great potential as a cancer therapeutic, both because of its impressive anti-tumor activity, and the potential for combination with other therapeutic antibodies, such as antibodies directed to CD20 or CD38.”